NCT02546934View on ClinicalTrials.gov

ABX Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC)

PHASE3CompletedINTERVENTIONAL
Enrollment

254

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

April 30, 2020

Study Completion Date

April 30, 2020

Conditions
Breast Cancer
Interventions
DRUG

ABX, cisplatin

ABX 125 mg/m2, IV drip 30 minutes, D1, D8 Cisplatin 75 mg/m2, IV drip 120 minutes, D1

DRUG

Gemcitabine, Cisplatin

Gemcitabine 1250 mg/m2, IV drip 30 minutes, D1, D8 Cisplatin 75 mg/m2, IV drip 120 minutes, D1

Trial Locations (1)

200032

Fudan University Cancer Hospital, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER

NCT02546934 - ABX Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC) | Biotech Hunter | Biotech Hunter